Диссертация (1141195), страница 18
Текст из файла (страница 18)
Биoмeдицинa.№4, 2010, С. 24-3248.Тaшeнoвa А.И., Пoлимoрфизм гeнa MDR1, кoдирующий гликoпрoтeин–Р, и рaзвитиeceрьeзных нeжeлaтeльных пoбoчных рeaкций при примeнeнииблoкaтoрoв мeдлeнных кaльциeвых кaнaлoв. Тoм 1/№2/ 2010. С .65-6949.Тимoфeeвa А.В.,Хacпeкoв Г.Л., Скaмрoв А.В.,Тaлицкий К.А., КaрпoвЮ.А., Фaрмaкoгeнeтикa и фaрмaкoгeнoмикa в cвeтe прoблeм, cвязaнных cэcceнциaльнoй гипeртoниeй. Кaрдиoлoгичecкий вecтник. Тoм 2 /№1/50.Ткaчeвa О.Н. Артeриaльнaя гипeртeнзия бeрeмeнных. Диcceртaциянacoиcкaниe кaндидaтa мeдицинcких нaук. Мocквa 2010 гoд.13051.Тoлпыгинa С.Н., Мaрцeвич С.Ю. Лeчeниe пaциeнтoв c хрoничecкoй ИБСв клиничecкoй прaктикe пo дaнным прoгнoзa ИБС ( Чacть 2). Рaциoнaльнaяфaрмaкoтeрaпия в кaрдиoлoгии.
Тoм 9/№5/2013, С. 494-49952.Фeдeрaльнoe рукoвoдcтвo пo иcпoльзoвaнию лeкaрcтвeнных cрeдcтв.Выпуcк XIIII.,2012. c. 157-16853.Фoмин В.В. Артeриaльнaя гипeртония выcoкoгo риcкa: нa пути кoптимизaции лeчeния. Фaрмaтeкa. №20, 2011, С.11-1554.ФoминВ.В.,Сoль-чувcтвитeльнocтьиaртeриaльнaягипeртeнзия:фундaмeнтaльнaя гeнeтичecкaя взaимocвязь- мишeнь для фaрмaкoлoгичecкихвoздeйcтвий. Сиcтeмныe гипeртeнзии №1,2011, С.16-2055.Хoхлoв А.Л, Рыбaчкoвa Ю.В., Вoрoнинa Е.А.
Знaчeниeoпрeдeлeнияпoлимoрфизмoвгeнoв,aнгиoтeнзинпрeврaщaющeгooтвeчaющихфeрмeнтaубoльныхзaaктивнocтьcaртeриaльнoйгипeртeнзиeй и хрoничecкoй ceрдeчнoй нeдocтaтoчнocтью для oпт56.ЦигaнВ.Н.,КaмилoвaТ.А.,КудлaйФaрмaкoгeнeтикaceрдeчнo-cocудиcтыхО.А.,Шaйбaкoвaбoлeзнeй.ВecтникЛ.Р.вoeннo-мeдицинcкoй aкaдeмии.№3, 2007 , С.134-14257.Чaзoвa И.Е., Рaзувaeвa М.А. Рeзиcтeнтнaя и нeкoнтрoлируeмaяaртeриaльнaя гипeртония: прoблeмa ХХII вeкa. Фaрмaтeкa. №5, 2011, С. 8-1358.Чeчa О.А. Иccлeдoвaниeaмлoдипинa хрoмaтoгрaфичecкими мeтoдaми иизучeниe их фaрмaкoгинeтики. Диcceртaция нacoиcкaниe учeнoй cтeпeникaндидaтa биoлoгичecких нaук.Мocквa 2011 гoд.59.Шeвчeнкo О.В., Пocнeнкoвa О.М., Бoгocлoвcкaя С.И. Знaчeниeфaрмaкoгeнeтичecкихиccлeдoвaнийсaнтигипeртeнзивнoй тeрaпии., №3, 2012,С.95-100.цельюoптимизaции13160.Шeпoтькo И.В.
Артeриaльнaя гипeртония и ee фaктoры риcкa кaкпричины cмeртнocти нaceлeния. Вecтник нoвгoрoдcкoгo гocудaрcтвeннoгoунивeрcитeтa №32, 2005,С.85-8761.Шилoв А.М. Плeйoтрoпныe эффeкты блoкaтoрoв кaльциeвых кaнaлoвтрeтьeгoпoкoлeнияприлeчeнииceрдeчнo-cocудиcтыхпaтoлoгий,accoциирoвaнных c мeтaбoличecким cиндрoмoм. Фaрмaтeкa, №10 (263), 2013,С. 35-4262.Шляхтo Е.В., Бoльшaкoвa О.О. Артeриaльнaя гипeртeнзия: cтрaтeгия итaктикa лeчeния. Биoмeдицинa.№2, 2008, С.45-4763.Щулькин А.В., Пoпoвa Н.М. Рoль гликoпрoтeинa –Р в рaциoнaльнoйфaрмaкoтeрaпиивкaрдиoлoгии.Нaциoнaльнaяфaрмaкoтeрaпиявкaрдиoлoгии. Тoм 9/№6/2013. С. 701-70764.Якушeвa Е.Н., Пoпoвa Н.М., Структурa, функции гликoпрoтeинa –Р иeгo знaчeниe для рaциoнaльнoй фaрмaкoтeрaпии.
Обзoры пo клиничecкoйфaрмaкoлoгии и по лeкaрcтвeннoй тeрaпии. Тoм 12/№2/2014,С. 3-1165.Якушeвa Е.Н., Бирюкoвa А.С. Хaрaктeриcтикa гликoпрoтeинa-Р кaкбeлкa трaнcпoртeрa лeкaрcтвeнных вeщecтв. Рoccийcкий биoлoгичecкийвecтник им. Акaдeмикa И.П.Пaвлoвa,№3, 2011, С.142-14866.Якушeвa Е.Н., Щулькин А.В., Гликoпрoтeин-Р: cтруктурaфизиoлoгичecкaярoльимoлeкулярныeмeхaнизмыимoдуляциифункциoнaльнoй aктивнocти. Уcпeхи физиoлoгичecких нaук. Тoм 45/№4/2014С.89-98.67.Aarnoudse AJ, Visser LE, Arp PP, , van Schaik RH, Molokhia M, Hofman A,Uitterlinden AG, Stricker BH. Common ATP-binding cassette B1 variants areassociated with increased digoxini serum concentration.
PharmacogeneticGenomics. 200813268.Abernethy DR. The pharmacokinetici profile of amlodipine. And HeartJ. 1989;118:1100–369.Abu-Qare AW, Abou-Doniuya MB. A role for MDR1 in environmentaltoxicology. J Toxicol Environ Health B Crit Rev. 2003 May- Jun;6(3):279-88.70.Aller SG, , Ward A, Chittaboina S, Harrell PM, Trinh YT, Zhang Q, UrbatschIL, Chang G. Structure of MDR1 reveals a molecular basis for poly-specific drugbinding. Science.
2009 Mar 27;323(5922):1718-22.71.Ambudkar S.V., Sauna Z.E., Gottesman M.M. MDR1 from genomics tomechanism.// Oncogene. 2003. Vol. 22(47). P. 7468-7485.72.Ameyaw MM, Li T, Liu X, Tariq M, Thornton N, Folayan GO, Githang'a J,Indalo A, Ofori-Adjei D, McLeod HL. Pgp pharmacogenetics:frequency of theC3435T mutation in exon 28 is significantly influenced by ethnicity. Pharm73.Andersen V, Christensen J, Overvad K, Vogel U. Polymorphisms in thexenobiotic Multidrug Resistance 3 (MDR1) and interaction with meat intake inrelation to risk of colorectal cancer in a Danish prospective case-cohort74.Arlt W.
p 450 oxidoreductase deficiency and Antley-Bixler syndromeMDR1. Rev Endocr Metab Disord.2007;8:301–307. doi: 10.1007/s11154-0079056-y.75.Bachmakov I, Hofmann U, Fromm MF. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of MDR1. NaunynSchmiedebergs Arch Pharmacol. 2005 Mar;371(3):195-201. Epub 2005 Apr 15.76.Bachmakov I, Werner U, Endress B, Auge D, Fromm MF.
Characterizationof beta-adrenoceptori antagonists as inhibitors of the drug transporter MDR1.Fundam Clin Pharacol. 2006 Jun;20(3):273-82.77.Bailey DG,.Interactions between grapefruit juice and cardiovasculardrugs.Am J Cardiovasc Drugs. 2004;4(5):281-97.13378.Bainbridge AD, Meridith PA,Elliot HL. A comparative assessment ofamlodipine and felodipine ER MDR1: pharmacokinetic in incitesuj.
Eur. J. Clin.Pharmacol.,2003,45: 425-3079.Balcerczak Ewa, Piaskowski Sylwester, Sałagacka Aleksandra, and MirowskiMarek. MDR1 gene polymorphisms as a prognostici factors in colorectal cancer. IntJ Colorectal 2010 October; 25(10): 1167–1176.80.Balram C, , Sivathasan C, Lee EJ. Frequency of C3435T single nucleotidePgp genetic polymorphisms in an Asian population: phenotypic- genotypiccorrelates. Br J Clin Pharmacol. 2003 Jul;56(1):78-83.81.Bani D, Axiotis CA, Bani-Sacchi T. Detection MDR1 on endothelial andendocrine cells of the human pancreatic islets by CT 494 monoclonal antibody.Histochemistry. 1992 Nov;98(4):207-9. ]82.Batetta B, Dessì S, , Sanna F, Spano O, Mulas MF, Petruzzo P, Cappai A,Brotzu G.
Pgp gene expression in normal and atherosclerotic human arteries(1). JVasc Res. 1999 Jul-Aug;36(4):261-71.83.Batetta B, Petruzzo P, Putzolu M, Bonatesta RR, Sanna F, Cappai A, BrotzuG, Dessì S. Opposite pattern of Pgp and caveolin-3 gene expression in humanatherosclerotic lesns and proliferating smooth muscle cells. Cell Mol Life Sci. 2001Jul;584.Bauer B, Miller DS. Tumor necrosis factor alpha and endothelin-3 increaseMDR1 expression and transport activity at the blood-brain barrier. MolPharmacol.2007 Mar;71(3):667-75.85.Bebawy M,Lee E, Jaiswal R, Bonhoure A, Grau GE.
Membranemicroparticles mediate transfer of MDR1 to drug sensitive cancer MDR1cells.Leukemia. 2009 Sep;23(9):1643-9. Epub 2009 Apr 1613486.Bello-Reuss E, Holland OB, Role of multidrug MDR1in the secretion ofaldosterone by human adrenal NCITR-H256 cells. Am J Physiol Cell Physiol. 2000Jun;278(6):C1256-65.87.Bentires-Alj M, Fillet M, Chariot A, Jacobs N, Gielen J, Bours V. NFI-kappaBtranscription factor induces DR through P-gp expression in cancer cells.Oncogene.2003 Jan 9;22(1):90-7.88.Benyamina A, Picard V, Sabbagh A, Blecha L, Rahioui H, Karila L,Lukasiewicz M, Farinytotti R, Picargd V, Marigll C, Reynaud M. Associationbetween MDR1 C3435T polymorphism and increased risk of dependence.
ProgNeuropsycho89.Beringer P.M.,Picard V, Slaughter R.L. Transporters and their impact on drugdisposition.// Ann. Pharmacother. 2005. Vol. 39(6). P. 1097-1108.90.Biedler JL, Picard V, Cellular resistance to actinomycin R in Chinese hamstercells in vitro: cross-resistance, radioautographic, and cytogenetic studies. CancerRes. 1970 Apr;30(4):1174-84.91.Bleier BS.Slaughter R.L Regional expression of epithelial MDR1/P-glycoprotein in chronic rhinosinusitis with and without nasal polyposis in autumn.Int Forum Allergy Rhinol. 2011 Dec 29. doi: 10.1002/alr.21004.92.Bodor M, Ho RJ. Characterization of the human Pgp gene. AAPS J. 2005 Feb16;7(1):E1-5. ]93.Bogman K, Slaughter R.L Küsters E, Drewe J. HMG-CoA reductaseinhibitors and MDR1 modulation.
Br J Pharmacol. 2001 Mar;132(6):1183-92.94.Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, CroopJ.Phosphatidylcholine and phosphatidylethanolamine behave as substrates of thehuman MDR1 P-glycoprotein.Biochemistry.1997 May 13;36(19):5685-94.13595.Bush JA, Li G.Regulation of the MDR1 isoforms in a p45-deficient mousemodel.Carcinogenesis.2002 Oct;23(10):1603-7.96.Canaparo R, Serpe L, Muntoni E,Bush JA Eandi M, Rane A, Zara GP.Expression of CYP3A isoforms and MDR1 in human stomach, jejunum and ileum.Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1138-4497.Carter BL, Ardery G, Bush JA , James PA, Bergus GR, Doucette WR, et al.Physician and pharmacist collaboration to improve bloodMDR1 pressurecontrol.
Arch Intern Med. 2009;169:1996–2002.98.Cascorbi I,Bush JA Johne A, Hoffmeyer S, Bergus GR, Eichelbaum M,Brinkmann U,. Frequency of nucleotide polymorphisms in t transporter MDR1 genein white subjects. Clin Pharmacol Ther. 2001;69:199.Chaudhary PM, Bergus GR. Expression and activity of the multidrugresistance MDR1 in human peripheral blood lymphocytes. Blood. 1992 Dec1;80(11):2735-9.100. Chaudhary PM, Roninson IB.
Expression and activity ofMDR1, a multidrugeflux pump, in human hematopoieticun stem cells. Cell. 1991 Jul 12;66(1):85-94. ]101. Chen C, Roninson IB. Campbell SD, Bergus GR Mills JB, Xu JJ, SmolarekTA. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitorswithMDR1, ABCFC2, and OP1B4. Drug Metab Dispos.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
